In cancer patients with brain metastases and type 2 diabetes, those using GLP-1 drugs had a 37% lower risk of death over 3 years. Significant mortality benefits were linked to semaglutide and ...

The U.S. Food and Drug Administration is reportedly mulling whether more prescription drugs should be sold over the counter (OTC) at pharmacies. In an interview on Wednesday, FDA commissioner Martin ...

Food and Drug Administration Commissioner Marty Makary told CNBC that his view is that "everything should be over the counter" unless a drug is unsafe, addictive or requires monitoring. He said the ...

For months, President Donald Trump and his aides touted efforts to lower prescription drug prices for Americans. Now consumers can check prices at the recently launched website TrumpRx.gov. "This is a ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...

At last week's launch of TrumpRx, President Trump described the discounted drug platform as "one of the most transformative health care initiatives of all time." But experts and health care advocates ...

President Donald Trump unveiled TrumpRx.gov, a new government-backed website aimed at giving Americans access to discounted prescription drugs. Speaking at the website launch Thursday evening at the ...

John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. Emory is the data editor at ...

This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation.

The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and ...

WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...